|Year : 2018 | Volume
| Issue : 1 | Page : 2-12
Prevention of stroke: Antihypertensives, cholesterol-lowering drugs, antithrombotics, anticoagulation, carotid surgery, and stenting
Department of Clinical Neurosciences and Prevention, Danube University Krems, Krems, Austria
|Date of Web Publication||29-Mar-2018|
Prof Michael Brainin
Department of Clinical Neurosciences and Prevention, Danube University Krems, 3500 Krems
Source of Support: None, Conflict of Interest: None
Antihypertensive drugs are very effective in secondary stroke prevention. More important than the choice of a class of antihypertensives is to achieve the systolic and diastolic blood pressure targets (<140/90 mmHg in nondiabetics and < 130/80 mmHg in diabetics). In many cases, this requires a combination therapy and lifestyle modification. Statin therapy reduces the rate of recurrent stroke and vascular events. The target range of low-density lipoprotein is 70–100 mg/dL. Patients with transient ischemic attack (TIA) or ischemic stroke should receive antiplatelet drugs. The choices are acetylsalicylic acid (ASA 50–150 mg) or clopidogrel (75 mg). Short-term use of dual antiplatelet therapy (ASA plus clopidogrel) may be considered in patients with acute minor stroke or TIA and high risk of recurrence. Patients with a cardiac source of embolism, in particular atrial fibrillation (AF), should be treated with oral anticoagulation. Options for patients with AF include dose-adjusted warfarin (international normalized ratio 2.0–3.0), apixaban, dabigatran, edoxaban, or rivaroxaban. Patients with contraindications to use oral anticoagulation should receive ASA 100–300 mg/day. Symptomatic patients with significant stenosis of the internal carotid artery (degree of stenosis between 70% and 95%) should undergo carotid endarterectomy. Carotid artery stenting is an alternative to endarterectomy in patients who are unsuitable or at high risk for endarterectomy. Patients should receive ASA before, during, and after endarterectomy or the combination of clopidogrel (75 mg) plus ASA (75–100 mg) and after carotid stenting for 1–3 months. Symptomatic patients with intracranial stenosis or occlusions should be treated with optimal medical management, which includes antiplatelet therapy and high-dose statins (if deemed appropriate). In patients with recurrent events, angioplasty can be considered.
Keywords: Anticoagulation, antihypertensive therapy, antithrombotics, aspirin, carotid stenting, carotid surgery, clopidogrel, stroke prevention
|How to cite this article:|
Brainin M. Prevention of stroke: Antihypertensives, cholesterol-lowering drugs, antithrombotics, anticoagulation, carotid surgery, and stenting. Hamdan Med J 2018;11:2-12
|How to cite this URL:|
Brainin M. Prevention of stroke: Antihypertensives, cholesterol-lowering drugs, antithrombotics, anticoagulation, carotid surgery, and stenting. Hamdan Med J [serial online] 2018 [cited 2020 Jul 4];11:2-12. Available from: http://www.hamdanjournal.org/text.asp?2018/11/1/2/228869
| Introduction|| |
Secondary prevention aims at preventing a stroke after a transient ischemic attack (TIA) or a recurrent stroke after a first stroke. About 80%–85% of patients survive a first ischemic stroke, of those between 8% and 15% suffer a recurrent stroke in the 1st year. Risk of stroke recurrence is highest in the first few weeks and declines over time., The risk of recurrence depends on concomitant vascular diseases (coronary heart disease [CHD], peripheral artery disease [PAD]) and vascular risk factors and can be estimated by risk models. Immediate evaluation of patients with stroke or TIA, identification of the pathophysiology, and initiation of pathophysiology-based treatment are of major importance.
| Antihypertensive Drugs|| |
Antihypertensive therapy reduces the risk of stroke. The combination of angiotensin-converting enzyme (ACE) inhibitors with a diuretic is more effective than placebo.
Angiotensin-receptor blocker (ARB) is more effective than calcium-channel blocker. Ramipril reduces vascular events in patients with vascular risk factors. Most likely, all antihypertensive drugs are effective in secondary stroke prevention. Beta-blockers, such as atenolol, show the lowest efficacy. More important than the choice of a class of antihypertensive is to achieve the systolic and diastolic blood pressure targets (<140/90 mmHg in nondiabetics and <130/80 mmHg in diabetics). The new target promoted by the ACC/AHA of systolic blood pressure <130 mmHg applies for primary stroke prevention. In many cases, this requires combination therapy. Concomitant diseases (kidney failure, congestive heart failure) have to be considered.
Lifestyle modification will lower blood pressure and should be recommended in addition to drug treatment.
Few studies investigated the efficacy of classes of antihypertensive drugs in secondary stroke prevention. One has to remember that two concepts exist in this field. Placebo-controlled trials may try to achieve a maximum lowering of blood pressure in patients with high blood pressure. Vascular protective studies such as the Heart Outcomes Prevention Evaluation (HOPE) study included patients with vascular risk factors even with normal blood pressure under the assumption that end organs such as the brain will be protected., A meta-analysis from 2003 comprised seven studies of 15,527 patients with TIA, or ischemic or hemorrhagic stroke, who were followed for 2–5 years. Treatment with antihypertensives reduced the risk of stroke by 24%, nonfatal stroke by 21%, risk of myocardial infarction (MI) by 21%, and risk of all vascular events by 21%. For the endpoint stroke, the combination of an ACE inhibitor with a diuretic was more effective (45% risk reduction) than a diuretic as monotherapy (32%), monotherapy with an ACE inhibitor (7%), or a beta-blocker (7%). A pairwise meta-analysis with 42.736 patients on antihypertensive treatment compared to placebo lowered the risk for recurrent stroke with a risk ratio of 0.73 (95% confidence interval [CI], 0.62–0.87). Systolic blood pressure was linearly related to lower risk of recurrent stroke.
ACE inhibitors and ARBs were thought to have pleiotropic and protective vascular effects beyond lowering high blood pressure. Therefore, the HOPE study compared ramipril with placebo. In the subgroup of patients with TIA or stroke as the qualifying event, ramipril resulted in a relative reduction of the combined endpoint of stroke, MI, or vascular death by 24% and an absolute risk reduction (ARR) of 6.3% in 5 years.
The Perindopril Protection Against Recurrent Stroke Study was the first large-scale trial specifically performed in patients after stroke. Patients (n = 6105) were treated with perindopril as monotherapy or in combination with indapamide (a diuretic) or placebo. Across the 4-year observation period, blood pressure was lowered on an average by 9/4 mmHg. The ARR for recurrent stroke was 4% and the relative risk reduction (RRR) was 28%. Monotherapy with the ACE inhibitor was not superior to placebo but also did not achieve the same level of blood pressure lowering as the combination therapy. The RRR for combination therapy was 43%.
The Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention (MOSES) study included 1352 patients with hypertension who had suffered a stroke in the previous 24 months. Patients were treated either with eprosartan (600 mg) or with nitrendipine (10 mg) on top of additional antihypertensive therapy when appropriate. For an identical drop in blood pressure, eprosartan was superior to nitrendipine in preventing recurrent vascular events (21% RRR). Optimal systolic blood pressure in the MOSES trial was 120–140 mmHg.
The Prevention Regimen For Effectively Avoiding Second Strokes (PRoFESS) study randomized 20,332 patients with a recent ischemic stroke to receive telmisartan at 80 mg/day or placebo in addition to other therapies, for a median duration of 2.4 years. Telmisartan did not significantly lower the rate of recurrent strokes, other major vascular events, or new diabetes.
The Secondary Prevention of Small Subcortical Strokes (SPS3) Trial randomized 3020 patients with recent, magnetic resonance imaging (MRI)-confirmed symptomatic lacunar strokes into two blood pressure target groups: 130–140 mmHg or <130 mmHg. Patients were followed up for a mean of 3.7 years. After 1 year, the mean blood pressure was 138 mmHg in the higher target group and 127 mmHg in the lower target group. There was no significant difference in the rate of recurrent stroke between the two groups, but the rate of intracerebral hemorrhage was significantly reduced in the lower target group.
In summary, antihypertensive therapy reduces the risk of ischemic and hemorrhagic stroke. Most likely, all antihypertensive drugs are effective in secondary stroke prevention. The optimal blood pressure target for secondary stroke prevention (<140 mmHg) and the most favorable timing for achieving this goal after the event remain unknown. In patients with lacunar stroke, there is no additional benefit with a lower systolic blood pressure target of <130 mmHg compared to the conventional target of <140 mmHg.
| Cholesterol-Lowering Drugs|| |
- Patients with TIA or ischemic stroke and CHD should be treated with a statin, irrespective of the initial low-density lipoprotein (LDL) cholesterol level. The target range of LDL is 70–100 mg/dL. Patients with atherosclerotic ischemic stroke or TIA without CHD and LDL cholesterol levels between 100 and 190 mg/dL will benefit from a treatment with 80 mg atorvastatin. Statin therapy reduces the rate of recurrent stroke and vascular events
- Lowering high LDL is more important than the use of a particular statin. Therefore, lowering LDL cholesterol <100 mg/dL or 50% of the initial LDL cholesterol level is recommended
- The possible benefit of PCSK9 inhibitors has not yet been shown for secondary stroke prevention.
The association of cholesterol levels and risk of recurrent stroke is not as strong as the association with the risk of MI. Statins lower the risk of stroke in patients with CHD. The RRR calculated from a meta-analysis is 21%. The AACE 2017 Guidelines recommend treating stroke patients with CHD with a statin. The LDL cholesterol level should be <100 and <70 mg/dL in high-risk patients.
Patients with stroke without CHD were investigated in a subgroup of the Heart Protection Study (HPS). Within the HPS patient population of 20,536 high-risk patients, 3280 patients had TIA or stroke, 1820 of them without concomitant CHD. The RRR achieved by 40 mg simvastatin given for 5 years for vascular events was 20% and the ARR 5.1%. In the overall population, the RRR for stroke was 25%, whereas there was no significant reduction in the stroke rate in the subgroup of patients with TIA or stroke as the qualifying event. Stroke Prevention by Aggressive Reduction in Cholesterol Levels was performed in 4731 patients with TIA or stroke without CHD and LDL cholesterol levels between 100 and 190 mg/dL. Patients received either 80 mg atorvastatin or placebo. After an average of 4.9 years, the primary endpoint (stroke) was reduced by 16% relative and 2.2% absolute. The RRR for the combined endpoint of stroke, MI, and vascular death was 20% and the ARR 3.5%. The rate of ischemic stroke was reduced (218 vs. 274), whereas hemorrhagic strokes were more frequent with atorvastatin (55 vs. 33). Recently, PCSK9 inhibitors were introduced to treat hypercholesterolemia. The number of patients with stroke included in these studies and the number of recurrent strokes were small. Therefore, the possible benefit of PCSK9 inhibitors at present is unclear but may be shown in the ongoing large endpoint trials.
Therapy with a statin should be initiated early after an ischemic stroke or TIA. The discontinuation of a statin in patients with a stroke or acute coronary syndrome might be associated with higher morbidity and mortality. Patients on a statin should continue treatment following an acute ischemic event. Patients with TIA or ischemic stroke and CHD should be treated with a statin, irrespective of the initial LDL cholesterol level.
| Diabetes Mellitus and Insulin Resistance|| |
Aggressive lowering of blood glucose in patients with diabetes mellitus does not reduce the risk of stroke and might even increase mortality. In a meta-analysis of three randomized controlled trials with 4.980 participants, use of pioglitazone in stroke patients with insulin resistance, prediabetes, and diabetes mellitus was associated with lower risk of recurrent stroke (hazard ratio [HR] 0.68; 95% CI, 0.50–0.92; P = 0.01) and future major vascular events (HR 0.75; 95% CI, 0.64–0.87; P = 0.0001). Empagliflozin reduces the risk of death due to heart failure but does not reduce the risk of stroke  Therefore, treatment of diabetes mellitus should not be restricted to drug treatment only but should also include diet, weight loss, and regular exercise.
| Antiplatelet Therapy|| |
- Patients with TIA or ischemic stroke should receive antiplatelet drugs. The choices are acetylsalicylic acid (ASA 50–150 mg), combination of ASA (2 mg × 25 mg), and extended-release dipyridamole (ER-DP, 2 mg × 200 mg) or clopidogrel (75 mg)
- ASA is recommended in patients with a low risk of recurrence (<4% per year). Patients with a higher risk of recurrent stroke should be treated with ASA + ER-DP or clopidogrel. ASA + ER-DP and clopidogrel appear to be equally effective. ASA + ER-DP has more side effects
- Doses of ASA >150 mg/day result in an increased risk of bleeding complications
- The combination of clopidogrel plus ASA is not more effective than either ASA or clopidogrel monotherapy and carries a higher bleeding risk
- Ticagrelor is not superior to aspirin in patients with TIA or minor stroke for prevention of the combination of stroke, MI, or death but may be superior for prevention of ischemic stroke.
The efficacy of antiplatelet therapy beyond 4 years after the initial event has not been studied in randomized trials. Theoretically, treatment should continue beyond that period.
- In the case of a recurrent ischemic event, the pathophysiology of the ischemic event should be evaluated. When there is an indication for antiplatelet therapy, the recurrence risk should be evaluated and the antiplatelet therapy adapted to the new risk. There is no evidence that changing antiplatelet therapy from ASA plus ER-DP to clopidogrel or vice versa provides greater protection
- Patients with a history of TIA or ischemic stroke and an acute coronary syndrome should receive the combination of clopidogrel and ASA for at least 3 months. The same is true for patients with a coronary stent. This therapy is also typically extrapolated to patients after stenting of the carotid or vertebral arteries
- In patients with lacunar stroke, there is no significant benefit of dual antiplatelet therapy with clopidogrel plus aspirin over aspirin alone. The combination increases the risk of hemorrhagic side effects
- A short-term course of dual antiplatelet therapy may be considered after an acute stroke or TIA.
Antiplatelet drugs are effective in secondary stroke prevention after TIA or ischemic stroke. This has been shown in many placebo-controlled trials and in several meta-analyses.,, The RRR for nonfatal stroke achieved by antiplatelet therapy in patients with TIA or stroke is 23% (reduced from 10.8% to 8.3% in 3 years). The combined endpoint of stroke, MI, and vascular death is reduced by 17% (from 21.4% to 17% in 29 months).
A meta-analysis of 11 randomized and placebo-controlled trials investigating ASA monotherapy in secondary stroke prevention found an RRR of 13% (95% CI, 6–19) for the combined endpoint of stroke, MI, and vascular death. The highest benefit of aspirin is in the early phase after the initial TIA or ischemic stroke  In a pooled analysis of 15,778 participants from 12 trials of aspirin versus control in secondary prevention, aspirin reduced the 6-week risk of recurrent ischemic stroke by about 60% (84 of 8452 participants in the aspirin group had an ischemic stroke vs. 175 of 7326; HR 0.42) and disabling or fatal ischemic stroke by about 70% (36 of 8452 vs. 110 of 7326; HR 0.29), with greatest benefit noted in patients presenting with TIA or minor stroke. There is no relationship between the dose of ASA and its efficacy in secondary stroke prevention., Therefore, the recommended dose of ASA is 75–150 mg/day. Gastrointestinal adverse events and bleeding complications are, however, dose dependent, and bleeding rates increase significantly beyond a daily ASA dose of 150 mg., Gastrointestinal bleeding complications in the elderly on aspirin can be prevented by proton-pump inhibitors. Clopidogrel monotherapy (75 mg/day) was compared to ASA (325 mg/day) in 19.185 patients with stroke, MI, or PAD in the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events trial. The combined endpoint of stroke, MI, and vascular death showed an RRR of 8.7% in favor of clopidogrel. The ARR was 0.51%. The highest benefit of clopidogrel was seen in patients with PAD. The risk of gastrointestinal bleeds (1.99% vs. 2.66%) and gastrointestinal side effects (15% vs. 17.6%) was smaller with clopidogrel than with ASA. The Molecular Analysis for Therapy CHoice (MATCH) study compared the combination of clopidogrel 75 mg and ASA 75 mg with clopidogrel monotherapy in high-risk patients with TIA or ischemic stroke  and failed to show the superiority of combination antiplatelet therapy for the combined endpoint of stroke, MI, vascular death, and hospitalization due to a vascular event. The combination of aspirin and clopidogrel resulted in a significant increase in bleeding complications and therefore is not recommended for long-term secondary stroke prevention.
The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial was a combined primary and secondary prevention study in 15,603 patients and compared the combination of clopidogrel and ASA with ASA monotherapy. Similar to MATCH, the study failed to show a benefit of combination therapy and displayed a higher bleeding rate with the combination of aspirin and clopidogrel. Symptomatic patients, however, showed a trend toward a benefit for combination antiplatelet therapy.
The combination of low-dose ASA and ER-DP was investigated in the second European Stroke Prevention Study with 6602 patients with TIA or stroke. Patients were randomized to ASA (25 mg bid), ER-DP (200 mg bid), the combination of ASA and ER-DP, or placebo. For the primary endpoint of stroke, the combination was superior to ASA monotherapy (RRR 23%, ARR 3%) and placebo (RRR 37%, ARR 5.8%).
ASA monotherapy lowered the risk of stroke by 18% (ARR 2.9%) and DP monotherapy by 16% (ARR 2.6%) compared to placebo. Major bleeding complications were seen more frequently with ASA and the ASA + ER-DP combination, whereas DP monotherapy had a similar bleeding rate to placebo. Cardiac events occurred at similar frequency in the groups treated with DP compared to ASA. The industry-independent European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) randomized 2739 patients with presumed atherothrombotic TIA or minor stroke to ASA (30–325 mg) or the combination of ASA with DP and followed them for a mean period of 3.5 years. The primary endpoint was the combination of vascular death, stroke, MI, and major bleeding complications. The event rate for the primary endpoint was 16% with ASA monotherapy and 13% with ASA + DP, resulting in an RRR of 20% (ARR 1%). In the combination arm, 34% of patients terminated the trial prematurely mostly because of adverse events such as headache (13% in the ASA arm of the study). A meta-analysis of all stroke prevention trials testing ASA monotherapy versus ASA + DP showed an RRR of 18% (95% CI 9–26) in favor of the combination for the combined vascular endpoint.
A head-to-head comparison of clopidogrel and ASA + ER-DP was performed in the PRoFESS study. The study randomized 20,332 patients with ischemic stroke and followed them for a mean period of 2.4 years. There was no difference in efficacy across all endpoints and no subgroup of patients. ASA + ER-DP resulted in more intracranial bleeds and a higher dropout rate due to headache compared with clopidogrel (5.9% vs. 0.9%).
[Table 1] gives an overview of ARR and RRR for different approaches in secondary stroke prevention.
|Table 1: Strategies for prevention of recurrent stroke after an initial transient ischemic attack or ischemic stroke|
Click here to view
Glycoprotein (GP)-IIb/IIIa receptor antagonists are effective in the acute coronary syndrome. Oral GP-IIb/IIIa-antagonists are not superior to ASA and carry a higher bleeding risk as shown in the BRAVO trial.
Ticagrelor was compared to aspirin in 13,199 patients with a nonsevere ischemic stroke or high-risk transient ischemic attack. Patients received either ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2 through 90) or aspirin (300 mg on day 1 followed by 100 mg daily for days 2 through 90). During the 90 days of treatment, stroke, MI, or death occurred in 442 of the 6589 patients (6.7%) treated with ticagrelor, versus 497 of the 6610 patients (7.5%) treated with aspirin (HR 0.89; 95% P = 0.07). The main secondary endpoint, ischemic stroke, occurred in 385 patients (5.8%) in the ticagrelor group and 441 patients (6.7%) in the aspirin group (HR 0.87; 95% CI, 0.76–1.00; P = 0.046). Major bleeding occurred in 0.5% of patients treated with ticagrelor and in 0.6% of patients treated with aspirin, intracranial hemorrhage in 0.2% and 0.3%, respectively, and fatal bleeding in 0.1% and 0.1%. In the SOCRATES study, ticagrelor was not found to be superior to aspirin in reducing the rate of stroke, MI, or death; however, there was a significant reduction in ischemic stroke. Long-term prevention with triflusal, terutroban, and vorapaxar or either not superior or have a higher bleeding risk compared to aspirin.
The use of dual antiplatelet therapy in patients with lacunar stroke was investigated in the SPS3 trial, which randomized 3020 patients with recent, MRI-confirmed symptomatic lacunar strokes into two antiplatelet groups: aspirin 325 mg daily and clopidogrel 75 mg daily versus aspirin 325 mg daily and placebo. Patients were followed up for a mean of 3.4 years. The primary outcome was reduction in all strokes, both ischemic and hemorrhagic. The risk of recurrent ischemic stroke was not significantly different between the two groups. The risk of major hemorrhage was significantly higher in the dual antiplatelet therapy group, 2.1% per year, compared with 1.1% per year risk in the aspirin-only group. Hence, there was no significant benefit of dual antiplatelet therapy in this patient population, and in fact, there is evidence that this combination leads to increased adverse events. The question of whether short-term use of aggressive, dual antiplatelet therapy in patients with acute minor stroke or TIA prevents recurrent stroke has been addressed in a randomized clinical trial in China. The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial randomized over 5000 Chinese patients with acute TIA or minor stroke to receive either clopidogrel initiated with a loading dose of 300 mg followed by 75 mg/day for the first 21 days or placebo. Both groups received aspirin 75 mg/day for a 3-month period. Patients were randomized within 24 h after TIA or stroke. The primary efficacy endpoint was any recurrent stroke (ischemic or hemorrhagic) at 3 months. The dual antiplatelet group had a significantly lower rate of any recurrent stroke (HR 0.68). The recurrent ischemic stroke rate was also significantly lower in the dual antiplatelet group compared to aspirin alone (7.9% vs. 11.4%, ARR 3.5%). The brain hemorrhage rates were surprisingly low with both groups having a rate of only 0.3%.
A similar North American and European trial called the Platelet Oriented Inhibition in New TIA and ischemic stroke (POINT) trial has recently completed enrollment but has not yet reported results. The POINT trial had a shorter randomization window compared with CHANCE (12 vs. 24 h) and a higher loading dose of clopidogrel (600 vs. 300 mg) (NCT00991029).
Patients with TIA or ischemic stroke should receive aspirin, clopidogrel, or aspirin plus ER-DP. Short-term use of dual antiplatelet therapy may be considered in patients with acute minor stroke or TIA and high risk of recurrence.
| Anticoagulation in Cerebral Ischemia Due to Cardiac Embolism|| |
- Patients with a high-risk cardiac source of embolism, in particular, atrial fibrillation (AF), should be treated with oral anticoagulation. Options for patients with AF include dose-adjusted warfarin (international normalized ratio [INR] 2.0–3.0) or the non-Vitamin K oral anticoagulants (NOACs) apixaban, dabigatran, edoxaban, or rivaroxaban
- Patients with contraindications or unwilling to use oral anticoagulation should receive ASA 81–325 mg/day. Patients with mechanical heart valves should be anticoagulated with an INR between 2.0 and 3.5, depending on the valve. NOACs are contraindicated in patients with moderate-to-severe mitral stenosis, rheumatic heart disease, or mechanical heart valves
- Patients with biological heart valves are anticoagulated for 3 months
- In patients with TIA or minor stroke, oral anticoagulation can be initiated immediately after the exclusion of cerebral hemorrhage
- The combination of ASA plus clopidogrel is inferior to oral anticoagulation with warfarin and carries a similar bleeding risk
- There is no evidence that the use of anticoagulation in patients with low left ventricular ejection fraction is superior to antiplatelet therapy.
The evidence that oral anticoagulation prevents recurrent strokes in patients with AF results from the European AF Trial. This randomized placebo-controlled trial showed a 68% RRR for recurrent stroke in patients treated with warfarin compared to only 19% of patients receiving 300 mg ASA. Numbers needed to treat (NNT) are 12 per year. Therefore, oral anticoagulation in patients with AF is by far the most effective treatment for secondary stroke prevention. A Cochrane analysis concluded that oral anticoagulation with warfarin is more effective than ASA for the prevention of vascular events (odds ratio [OR] 0.67; 95% CI, 0.50–0.91) or recurrent stroke (OR 0.49; 95% CI, 0.33–0.72). The risk of major bleeding complications is significantly increased but not the risk of intracranial bleeds. Patients with intermittent AF have a similar stroke risk to patients with permanent AF. The optimal INR range for oral anticoagulation is between 2.0 and 3.0. INR values >3.0 lead to an increased risk of major bleeding complications, in particular in the elderly.
The ACTIVE study compared the combination of ASA and clopidogrel versus oral anticoagulation with warfarin in patients with AF: the study was terminated prematurely due to a significant reduction of stroke and systemic embolism in favor of warfarin. The rate of major bleeding complications was not different between the two treatment regimens.
Since 2009, four NOACs have become available as an alternative to dose-adjusted warfarin in nonvalvular AF: apixaban, dabigatran, edoxaban, and rivaroxaban.
Dabigatran is a direct thrombin inhibitor, which was compared with warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. In RE-LY, 18,113 patients were randomly assigned to receive dabigatran 150 mg twice daily, dabigatran 110 mg twice daily, or dose-adjusted warfarin. Patients were followed for a mean of 2 years. The primary outcome was hemorrhagic stroke, ischemic stroke, or systemic embolism. The 150 mg dabigatran group had a significantly lower rate of the primary outcome compared with the warfarin group (1.11% per year for dabigatran vs. 1.69% per year for warfarin, P ≤ 0.001 for superiority) and had a similar rate of major bleeding (3.11% per year for dabigatran vs. 3.36% per year in the warfarin group, P = 0.31). The 110 mg dabigatran group had a similar rate of the primary outcome compared with warfarin (1.53% per year for dabigatran vs. 1.69% per year for warfarin, P < 0.001 for noninferiority) but had a lower risk of hemorrhagic stroke (2.71% per year for dabigatran vs. 3.36% per year for warfarin).
Rivaroxaban, a factor X inhibitor, was compared with warfarin in the ROCKET AF trial. In the trial, 14,264 patients with nonvalvular AF and at increased risk for stroke were randomized to receive either rivaroxaban 20 mg daily or dose-adjusted warfarin. The primary endpoint was hemorrhagic stroke, ischemic stroke, or systemic embolism. The median follow-up was 1.9 years. In the intention-to-treat analysis, the rate of the primary endpoint was 2.1% per year for the rivaroxaban group compared with 2.4% per year in the warfarin group (P< 0.001 for noninferiority). The rate of major and nonmajor clinically relevant bleeding was not significantly different between the two groups (14.9% per year for rivaroxaban vs. 14.5% per year for warfarin, P = 0.44).
The ARISTOTLE trial compared another factor X inhibitor, apixaban, with warfarin. The trial randomized 18,201 patients with AF and at least one additional stroke risk factor to either apixaban 5 mg twice a day or dose-adjusted warfarin. The primary outcome was a combination of hemorrhagic stroke, ischemic stroke, or systemic embolism. The median follow-up was 1.8 years. The rate of the primary outcome was 1.27% per year in the apixaban group versus 1.60% per year in the warfarin group (P< 0.001 for noninferiority and P = 0.01 for superiority). The rate of major bleeding was lower in the apixaban group compared to the warfarin group: 2.13% per year for apixaban and 3.09% per year for warfarin (P< 0.001).
The AVERROES trial evaluated apixaban 5 mg twice daily versus aspirin 81–324 mg daily in patients with AF and increased risk of stroke that was felt to be unsuitable for Vitamin K antagonist therapy. Patients were followed for a mean of 1.1 years for the primary outcome of stroke (hemorrhagic or ischemic) or systemic embolism. The study was terminated early as recommended by the data safety monitoring board because of a clear benefit in favor of apixaban.
ENGAGE-AF was a randomized, double-blind, double-dummy trial comparing two once daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk AF. The annualized rate of the primary endpoint (stroke or systemic embolism) during treatment was 1.50% with warfarin, as compared with 1.18% with high-dose edoxaban (HR 0.79; 97.5% CI, 0.63–0.99) and 1.61% with low-dose edoxaban (HR 1.07; 97.5% CI, 0.87–1.31). In the intention-to-treat analysis, there were a trend favoring high-dose edoxaban versus warfarin (HR 0.87; 97.5% CI, 0.73–1.04; P = 0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (HR 1.13; 97.5% CI, 0.96–1.34; P = 0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (HR 0.80; 95% CI, 0.71–0.91; P < 0.001) and 1.61% with low-dose edoxaban (HR 0.47; 95% CI, 0.41–0.55; P < 0.001).
All studies comparing NOACs with warfarin had a subgroup of AF patients with a prior TIA or stroke. In contrast to the patients included in the overall trials, patients with a prior TIA or stroke were comparable in terms of risk factors and concomitant diseases at baseline. In 20,500 patients, compared to warfarin, non-Vitamin K antagonist oral anticoagulants were associated with a significant reduction of stroke/systemic embolism (RRR 13.7%, ARR 0.78%, NNT to prevent one event 127), hemorrhagic stroke (RRR 50.0%, ARR 0.63%, NNT 157), any stroke (RRR 13.1%, ARR 0.7%, NNT 142), and intracranial hemorrhage (RRR 46.1%, ARR 0.88%, NNT 113) over 1.8–2.8 years. Therefore, NOACs should be preferred over warfarin in secondary stroke prevention in patients with AF.
The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial was designed to determine whether anticoagulation was superior to antiplatelet therapy in patients with heart failure and low left ventricular ejection fraction. The trial randomized 2305 patients to either dose-adjusted warfarin with a target INR range of 2.0–3.5 or aspirin 325 mg daily. The mean follow-up was 3.5 years and the primary outcome was a composite endpoint of ischemic stroke, intracerebral hemorrhage, or death from any cause. The rate of the primary outcome was not significantly different between the two groups: 7.47 events per 100 patient-years in the warfarin group and 7.93 in the aspirin group (P = 0.40). The warfarin group had a lower rate of ischemic stroke compared to aspirin: 0.72 events per 100 patient-years for warfarin versus 1.36 per 100 patient-years for aspirin (P = 0.005). However, as expected, the rate of major hemorrhage was higher in the warfarin group: 1.78 events per 100 patient-years for warfarin as opposed to 0.87 for aspirin (P< 0.001).
At present, there are only few data as to when it is safe to initiate oral anticoagulation after a TIA or ischemic stroke.,, Patients with acute ischemic events were excluded from the trials with the novel anticoagulants. A common recommendation is to start anticoagulation in patients with TIA on day 1, in patients with mild strokes on day 3, and in patients with moderate strokes on day 6. In patients with severe stroke, anticoagulation can be initiated after 2 weeks provided that a repeat computed tomography (CT) does not show major hemorrhagic transformation.
Patients with a cardiac source of embolism, in particular, AF, should be treated with oral anticoagulation. Options include dose-adjusted warfarin (INR 2.0–3.0), apixaban, dabigatran, edoxaban, and rivaroxaban.
| Anticoagulation in Cerebral Ischemia of Noncardiac Origin|| |
- Oral anticoagulation is not superior to ASA and is not recommended
- The benefit of anticoagulation for patients with dissection of the vertebral or carotid arteries versus antiplatelet drugs has not been studied in head-to-head trials
- Patients with cryptogenic stroke and coagulation disorders, for example, protein C or S deficiency or factor V (Leiden) mutation, may benefit from oral anticoagulation. The optimal treatment duration and specific coagulation disorders that warrant anticoagulation are not clear.
The Stroke Prevention in Reversible Ischemia Trial studied oral anticoagulation with an INR between 3.0 and 4.5 versus ASA 30 mg in patients with TIA or minor stroke without a cardiac source of embolism. The study was terminated due to a significantly increased bleeding risk with anticoagulation. The risk of bleeding was increased by a factor of 1.43 (95% CI, 0.96–2.13) for an increase of the INR by 0.5. The Warfarin Aspirin Recurrent Stroke Study had a similar rate of ischemic events and bleeding complications comparing warfarin (INR 1.4–2.8) and ASA in stroke patients without a cardiac source of embolism. This result was replicated in the ESPRIT study. ESPRIT found a lower rate of ischemic events with anticoagulation counterbalanced by an increased risk of intracranial bleeds.
A Cochrane analysis of five trials, with 4076 patients, was unable to show that anticoagulants are more or less efficacious in the prevention of vascular events than antiplatelet therapy (medium-intensity anticoagulation relative risk [RR] 0.96; 95% CI, 0.38–2.42; high-intensity anticoagulation RR 1.02; 95% CI, 0.49–2.13). The RR of major bleeding complications for low-intensity anticoagulation was 1.27 (95% CI, 0.79–2.03) and for medium-intensity anticoagulation 1.19 (95% CI, 0.59–2.41). High-intensity oral anticoagulants with INR 3.0–4.5 resulted in a higher risk of major bleeding complications (RR 9.0; 95% CI, 3.9–21).
The Antiphospholipid Antibodies and Stroke Study found no difference in stroke, MI, or vascular death in patients with antiphospholipid antibodies (aPL) treated with warfarin (INR 1.4–2.8) compared to 325 mg ASA. There was in addition no difference in event rates between patients positive or negative for aPL. The evidence for anticoagulation in patients with protein C, protein S, or antithrombin deficiency is derived from patients with deep vein thrombosis and not from patients with stroke.
The possible benefit of oral anticoagulation, compared with antiplatelet drugs, for the long-term treatment of dissections, was studied in the CADISS trial. The study recruited 250 patients with dissections of the carotid and vertebral arteries. Overall, four (2%) of 250 patients had stroke recurrence (all ipsilateral). Stroke or death occurred in three (2%) of 126 patients versus one (1%) of 124 (OR 0.335; 95% CI, 0.006–4.233; P = 0.63) has never been studied in a randomized trial. A Cochrane review of 26 observational studies in 327 patients found no difference between anticoagulation and antiplatelet drugs for the endpoints death and severe disability. Observational data indicate that NOACs might be as effective as warfarin with a better safety profile.
| Carotid Endarterectomy and Stenting With Balloon Angioplasty|| |
- Symptomatic patients with significant stenosis of the internal carotid artery (ICA) should undergo carotid endarterectomy. The benefit of surgery increases with the degree of stenosis between 70% and 95%. The benefit of surgery is highest in the first 2–4 weeks after the initial TIA or minor stroke
- The benefit of surgery is lower in patients with stenosis between 50% and 70%, in high-degree stenosis (pseudo-occlusion), in women, and in cases when surgery is performed 12 weeks or later after the initial event
- The benefit of surgery is no longer present when the complication rate exceeds 6%
- Patients should receive ASA before, during, and after endarterectomy. Clopidogrel should be replaced by ASA 5 days before surgery
- At present, carotid stenting has a slightly higher short-term complication rate and similar medium-term outcomes. The use of protection systems does not decrease the complication rate. The restenosis rate is higher after stenting
- Whether this translates into higher long-term event rates is not yet known. The complication rate of carotid stenting is age dependent and increases beyond the age of 65–68 years
- The combination of clopidogrel (75 mg) plus ASA (75–100 mg) is recommended in patients after carotid stenting for 1–3 months based on extrapolation from studies of coronary stents.
Two large randomized trials (NASCET and ESC) found a clear benefit of carotid surgery compared to medical treatment in patients with high-degree stenosis of the ICA. Taken together the trials found an ARR of 13.5% over 5 years for the combined endpoint of stroke and death in favor of carotid endarterectomy. The risk reduction is even higher in stenosis >90%. In patients with 50%–69% ICA stenosis, the 5-year ARR for the endpoint ipsilateral stroke is 4.6%. This benefit is mainly seen in males. Patients with <50% ICA stenosis do not benefit from carotid endarterectomy. The short-term complication rates (stroke and death) were 6.2% for stenosis >70% and 8.4% for 50%–69% stenosis. ASA should be given before, during, and after carotid surgery.
Several studies randomized patients with significant ICA stenosis to carotid endarterectomy or balloon angioplasty with stenting. Surgeons and interventional neuroradiologists had to pass a quality control. SPACE randomized 1200 symptomatic patients with a >50% stenosis (NASCET criteria) or >70% (ESC criteria) within 6 months after TIA or minor stroke to carotid endarterectomy or stenting. The primary endpoint, ipsilateral stroke or death within 30 days, was 6.84% in patients undergoing stenting and 6.34% in patients who were operated on. A post hoc subgroup analysis identified age < 68 years as a factor in a lower complication rate in patients treated with stenting. The complication rate of surgery was not age dependent. The use of a protection system did not influence the complication rate. The EVA3S study was terminated prematurely after 527 patients were randomized due to a significant difference in the 30-day complication rate favoring carotid surgery (9.6% vs. 3.9%; OR 2.5; 95% CI, 1.25–4.93). Taken together, the results of the two studies show a lower complication rate for endarterectomy. The reported medium-term outcomes were comparable, and the restenosis rate was higher after carotid stenting.
The Carotid Revascularization Endarterectomy versus Stenting trial compared stenting versus endarterectomy for the treatment of carotid artery stenosis. Patients who were either symptomatic or asymptomatic were included in the study. Patients were considered symptomatic if they experienced a TIA, amaurosis fugax, or minor nondisabling stroke in the territory of the study carotid artery within 180 days before randomization. Symptomatic patients were required to have stenosis of 50% or more on angiography, 70% or more on ultrasonography, or 70% or more on CT angiography or magnetic resonance angiography to be included in the study. Asymptomatic patients were eligible to participate if the degree of carotid stenosis was 60% or more on angiography, 70% or more on ultrasonography, or 80% or more on CT angiography or magnetic resonance angiography. The primary endpoint was a composite of either (1) stroke, MI, or death from any cause during the periprocedural period or (2) any ipsilateral stroke within 4 years after randomization. The study followed 2502 patients for a median follow-up period of 2.5 years. The estimated 4-year rate of the primary endpoint was not significantly different between the two groups (7.2% for stenting and 6.8% for endarterectomy, P = 0.51). However, there was a difference in the periprocedural risk of stroke and MI between the two groups. The rate of periprocedural stroke was higher in the stenting group (4.1% for stenting vs. 2.3% for endarterectomy, P = 0.01) whereas the risk of periprocedural MI was higher in the endarterectomy group (1.1% for stenting vs. 2.3% for endarterectomy, P = 0.03). The rate of ischemic stroke after the periprocedural period was similar between the groups (2.0% and 2.4%, respectively; P = 0.85). Finally, there was a significant relationship between age and treatment efficacy (P = 0.02): patients aged <70 years tended to do better with stenting whereas those aged >70 years did better with endarterectomy. The Vertebral artery Ischemic Stenting Trial compared stenting versus best medical treatment in patients with symptomatic stenosis of the vertebral arteries. The study did not observe a difference but was underpowered.
Symptomatic patients with significant stenosis of the ICA should undergo carotid endarterectomy. Carotid artery stenting is a reasonable alternative to endarterectomy in patients who are deemed to be unsuitable or at high risk for endarterectomy.
| Intracranial Stenosis|| |
- Symptomatic patients with intracranial stenosis or occlusions should be treated with antiplatelet therapy
- In patients with recurrent events, angioplasty can be considered.
The WASID-II study recruited 569 patients with intracranial stenosis and randomized them to either oral anticoagulation (INR 2.0–3.0) or ASA (1300 mg/day). The study was terminated prematurely due to a higher rate of bleeding complications with warfarin. Therefore, ASA is recommended in these patients. Whether the high dose of ASA is needed is not known. Lower doses are better tolerated and appear to have equal efficacy in other ischemic stroke etiologies. Predictors for a recurrent ischemic event were the degree of stenosis, stenosis in the vertebrobasilar system, and female sex.
The Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis trial randomized patients with recent TIA or stroke due to high-grade intracranial stenosis (70%–99%) to aggressive medical management alone or aggressive medical management plus stenting. The primary endpoint was either (1) stroke or death within 30 days after enrollment or after a revascularization procedure or (2) stroke in the territory of the qualifying artery beyond 30 days. Enrollment was stopped early after 451 patients were randomized because the 30-day rate of stroke or death was 14.7% in the stenting arm and only 5.8% in the medical management group (P< 0.002). One-year rates of the primary endpoint were 20.0% in the stenting group and 12.2% in the medical management group. Given the significantly higher stroke rates in the stenting arm, patients with TIA or stroke due to intracranial stenosis should typically be managed with medical therapy alone. If recurrent stroke or TIA events occur in the distribution of the stenotic intracranial vessel despite optimal medical management, then angioplasty (preferably without stenting) may be considered. However, there are no randomized clinical trials comparing medical management alone with medical management and angioplasty without stenting in patients with intracranial stenosis.
The contribution of Prof. Chris Diener, Essen, Germany, is appreciated.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al.
Risk factors, outcome, and treatment in subtypes of ischemic stroke: The german stroke data bank. Stroke 2001;32:2559-66.
Amarenco P, Lavallee PC, Labreuche J, Albers GW, Bornstein NM, Canhao P, et al
. One-year risk of stroke after transient ischemic attack or minor stroke. N
Engl J Med 2016;374:1533-42.
Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004;62:569-73.
Knoflach M, Lang W, Seyfang L, Fertl E, Oberndorfer S, Daniel G, et al.
Predictive value of ABCD2 and ABCD3-I scores in TIA and minor stroke in the stroke unit setting. Neurology 2016;87:861-9.
Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN,et al
. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): A prospective population-based sequential comparison. Lancet 2007;370:1432-42.
Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al
. Telmisartan, ramipril, or both in patients at high risk for vascular events. N
Engl J Med 2008;358:1547-59.
Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: A systematic review. Stroke 2003;34:2741-8.
Katsanos AH, Filippatou A, Manios E, Deftereos S, Parissis J, Frogoudaki A, et al.
Blood pressure reduction and secondary stroke prevention: A systematic review and metaregression analysis of randomized clinical trials. Hypertension 2017;69:171-9.
Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al.
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-inhibitor myocardial infarction collaborative group. Lancet 2000;355:1575-81.
Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al.
Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-26.
Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al.
Telmisartan to prevent recurrent stroke and cardiovascular events. N
Engl J Med 2008;359:1225-37.
Elkind MS, Luna JM, McClure LA, Zhang Y, Coffey CS, Roldan A, et al.
C-reactive protein as a prognostic marker after lacunar stroke: Levels of inflammatory markers in the treatment of stroke study. Stroke 2014;45:707-16.
Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-analysis. Stroke 2004;35:2902-9.
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al.
American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 2017;23:1-87.
Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67.
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N
Engl J Med 2006;355:549-59.
Milionis H, Barkas F, Ntaios G, Papavasileiou V, Vemmos K, Michel P, et al.
Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk. Eur J Intern Med 2016;34:54-7.
Blanco M, Nombela F, Castellanos M, Rodriguez-Yáñez M, García-Gil M, Leira R, et al.
Statin treatment withdrawal in ischemic stroke: A controlled randomized study. Neurology 2007;69:904-10.
Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al.
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72.
Lee M, Saver JL, Liao HW, Lin CH, Ovbiagele B. Pioglitazone for secondary stroke prevention: A systematic review and meta-analysis. Stroke 2017;48:388-93.
Zinman B, Inzucchi SE, Lachin JM, Wanner C, Fitchett D, Kohler S, et al.
Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke 2017;48:1218-25.
Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
Born G, Patrono C. Antiplatelet drugs. Br J Pharmacol 2006;147 Suppl 1:S241-51.
Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999;66:255.
Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z, et al.
Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: Time-course analysis of randomised trials. Lancet 2016;388:365-75.
Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N
Engl J Med 2005;353:2373-83.
Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, et al.
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399-406.
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al.
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N
Engl J Med 2001;345:494-502.
Li L, Geraghty OC, Mehta Z, Rothwell PM; Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: A population-based cohort study. Lancet 2017;390:490-9.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee. Lancet 1996;348:1329-39.
Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al.
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al.
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N
Engl J Med 2006;354:1706-17.
Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al.
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982-8.
Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A, et al.
European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-3.
Diener HC, Darius H, Bertrand-Hardy JM, Humphreys M; European Stroke Prevention Study 2. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001;55:162-3.
ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A, et al.
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet 2006;367:1665-73.
Diener HC, Sacco R, Yusuf S; Steering Committee; PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007;23:368-80.
Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al
. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N
Engl J Med 2016.
Hankey GJ. Stroke. Lancet 2017;389:641-54.
SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, et al.
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N
Engl J Med 2012;367:817-25.
Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al.
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N
Engl J Med 2013;369:11-9.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al.
2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962.
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-62.
Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Stroke 2004;35:1782-3.
Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW, et al.
Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: Frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis 2000;10:39-43.
Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96.
ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, et al.
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): A randomised controlled trial. Lancet 2006;367:1903-12.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.
Dabigatran versus warfarin in patients with atrial fibrillation. N
Engl J Med 2009;361:1139-51.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al.
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N
Engl J Med 2011;365:883-91.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.
Apixaban versus warfarin in patients with atrial fibrillation. N
Engl J Med 2011;365:981-92.
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al.
Apixaban in patients with atrial fibrillation. N
Engl J Med 2011;364:806-17.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al.
Edoxaban versus warfarin in patients with atrial fibrillation. N
Engl J Med 2013;369:2093-104.
Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 2017;12:589-96.
Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al.
Warfarin and aspirin in patients with heart failure and sinus rhythm. N
Engl J Med 2012;366:1859-69.
Paciaroni M, Agnelli G, Caso V, Tsivgoulis G, Furie KL, Tadi P, et al.
Prediction of early recurrent thromboembolic event and major bleeding in patients with acute stroke and atrial fibrillation by a risk stratification schema: The ALESSA score study. Stroke 2017;48:726-32.
Paciaroni M, Agnelli G, Ageno W, Caso V. Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. Thromb Haemost 2016;116:410-6.
Arihiro S, Todo K, Koga M, Furui E, Kinoshita N, Kimura K, et al.
Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-nonvalvular atrial fibrillation (NVAF) study. Int J Stroke 2016;11:565-74.
A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997;42:857-65.
Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al.
Acomparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N
Engl J Med 2001;345:1444-51.
ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A, et al.
Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): A randomised controlled trial. Lancet Neurol 2007;6:115-24.
Algra A, De Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2006:CD001342.
Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, et al.
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004;291:576-84.
CADISS trial investigators, Markus HS, Hayter E, Levi C, Feldman A, Venables G, et al.
Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): A randomised trial. Lancet Neurol 2015;14:361-7.
Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection. Stroke 2004;35:613-4.
Caprio FZ, Bernstein RA, Alberts MJ, Curran Y, Bergman D, Korutz AW, et al.
Efficacy and safety of novel oral anticoagulants in patients with cervical artery dissections. Cerebrovasc Dis 2014;38:247-53.
Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, et al.
Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N
Engl J Med 1998;339:1415-25.
Chaturvedi S, Bruno A, Feasby T, Holloway R, Benavente O, Cohen SN, et al.
Carotid endarterectomy – an evidence-based review: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2005;65:794-801.
SPACE Collaborative Group, Ringleb PA, Allenberg J, Brückmann H, Eckstein HH, Fraedrich G, et al.
30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: A randomised non-inferiority trial. Lancet 2006;368:1239-47.
Stingele R, Berger J, Alfke K, Eckstein HH, Fraedrich G, Allenberg J, et al.
Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: A subanalysis of the SPACE study. Lancet Neurol 2008;7:216-22.
Brott TG, Hobson RW 2nd
, Howard G, Roubin GS, Clark WM, Brooks W, et al
. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N
Engl J Med 2010;363:11-23.
Markus HS, Larsson SC, Kuker W, Schulz UG, Ford I, Rothwell PM, et al.
Stenting for symptomatic vertebral artery stenosis: The vertebral artery ischaemia stenting trial. Neurology 2017;89:1229-36.
Bonati LH, Lyrer P, Ederle J, Featherstone R, Brown MM. Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev 2012:CD000515.
Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al.
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N
Engl J Med 2005;352:1305-16.
Kasner SE, Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, et al.
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006;113:555-63.
Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al.
Stenting versus aggressive medical therapy for intracranial arterial stenosis. N
Engl J Med 2011;365:993-1003.